Colchicine product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 10:21
Colchicine product-specific bioequivalence guidance
Ticagrelor product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 10:09
Ticagrelor product-specific bioequivalence guidance
Emtricitabine / rilpivirine / tenofovir disoproxil product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 10:06
Emtricitabine / rilpivirine / tenofovir disoproxil product-specific bioequivalence guidance
Rilpivirine product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 10:03
Rilpivirine product-specific bioequivalence guidance
Rivaroxaban product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 9:59
Rivaroxaban product-specific bioequivalence guidance
Sitagliptin product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 9:56
Sitagliptin product-specific bioequivalence guidance
Tacrolimus granules product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 9:51
Tacrolimus granules product-specific bioequivalence guidance
Human medicines European public assessment report (EPAR): Xgeva, denosumab, Date of authorisation: 13/07/2011, Revision: 27, Status: Authorised
Submitted by Anonymous (not verified) on 29 July 2025 - 17:00
Human medicines European public assessment report (EPAR): Xgeva, denosumab, Date of authorisation: 13/07/2011, Revision: 27, Status: Authorised
PSUSA/00000375/202410
Submitted by Anonymous (not verified) on 29 July 2025 - 15:45
PSUSA/00000375/202410
PSUSA/00001911/202412
Submitted by Anonymous (not verified) on 29 July 2025 - 15:44
PSUSA/00001911/202412